Breast implants are widely used in both aesthetic and reconstructive surgery. For many patients, they can be part of body image, quality of life, or breast reconstruction after cancer treatment. However, like any medical device, breast implants are not free of risks. In recent years, one rare but important complication has received increasing scientific attention: breast implant-associated anaplastic large cell lymphoma, commonly known as BIA-ALCL.
BIA-ALCL is not a typical breast cancer. It does not usually originate in the glandular breast tissue, as most breast cancers do. Instead, it is a rare malignancy of immune cells, specifically T lymphocytes, that usually develops in the fluid or in the scar tissue capsule surrounding a breast implant. This distinction is important because the biology, diagnosis, treatment, and prognosis of BIA-ALCL are different from those of conventional breast cancer.
Most reported cases appear years after implant placement, often presenting as a delayed accumulation of fluid around the implant, known as a late seroma. Less commonly, patients may develop a mass near the implant capsule, lymph node involvement, or more advanced disease.
For this reason, specialists often describe it as a cancer of the immune system that occurs in the periprosthetic capsule, rather than breast cancer in the traditional sense.
Textured implants
One of the strongest observations in the scientific literature is the association between BIA-ALCL and textured breast implants. Textured implants have a rougher surface designed to help the implant adhere to the surrounding tissue and reduce movement. However, this surface may also create a more favorable environment for chronic inflammation, bacterial biofilm formation, and prolonged immune stimulation.
The exact cause of BIA-ALCL has not been fully established. Current hypotheses suggest that several factors may interact over time: the type of implant, bacterial contamination or biofilm formation, chronic inflammation, genetic susceptibility, and immune signaling pathways. In other words, BIA-ALCL is unlikely to be explained by a single mechanism. It appears to be the result of a long-term interaction between the medical device, the local tissue environment, and the immune system.
Chronic inflammation
When a breast implant is placed, the body naturally forms a thin layer of scar tissue around it, known as the capsule. This is a normal foreign body reaction. In most people, this capsule remains stable and does not cause major problems. But in some cases, especially when chronic irritation or bacterial biofilm is present, the immune system may remain persistently activated.
Persistent immune activation can create a microenvironment rich in cytokines, inflammatory cells, and cell survival signals. Over the years, this may increase the possibility that certain T lymphocytes acquire abnormal features. Some studies have suggested that molecular pathways such as JAK/STAT signaling may play a role in the development or maintenance of BIA-ALCL. This does not mean that inflammation alone causes cancer, but it may help explain how a rare lymphoma can emerge in a chronically stimulated tissue environment.
Figure 1. Textured breast implants may promote bacterial adhesion, chronic immune activation, and long-term T-cell stimulation, contributing to BIA-ALCL development around the implant capsule or fluid. Early recognition of symptoms and timely diagnosis are essential for better outcomes.
What symptoms should raise concern?
The most common warning sign is persistent breast swelling, especially if it appears years after implant placement. This swelling is usually caused by fluid accumulation around the implant. Other possible signs include breast pain, a palpable mass, asymmetry, changes in breast shape, skin changes, or swollen lymph nodes.
These symptoms do not automatically mean cancer. Many implant-related changes are benign, such as rupture, capsular contracture, infection, or mechanical complications. However, any new, persistent, or unexplained change around a breast implant should be evaluated by a qualified healthcare professional. Early assessment is important because BIA-ALCL is often highly treatable when detected in its early stages.
How is BIA-ALCL Diagnosed?
Diagnosis usually begins with clinical evaluation and imaging studies, often with ultrasound. If there is fluid around the implant, a sample may be collected for analysis. Laboratory evaluation is essential because BIA-ALCL cells usually express a receptor called CD30, which is an important diagnostic marker. Pathology and immunohistochemistry help distinguish BIA-ALCL from infection, benign seroma, other lymphomas, or breast carcinoma.
If a mass is present, a tissue biopsy may be required. Once the diagnosis is confirmed, additional imaging studies may be used to evaluate whether the disease is localized to the capsule or has spread to lymph nodes or other sites. This staging process guides treatment decisions.
How serious is BIA-ALCL?
Although BIA-ALCL is rare, it should be taken seriously. The FDA notes that the individual risk of developing it is low, but that it can be a serious and even life-threatening disease if it is not diagnosed and treated in a timely manner.
The prognosis is usually favorable when BIA-ALCL is diagnosed in early stages and complete removal of the implant and surrounding capsule is performed. Clinical studies have reported approximate overall survival rates of 94% at 3 years and 91% at 5 years. In addition, when the disease is localized and complete surgery is achieved, disease control can be very high.
However, the risk increases when there is a mass, lymph node involvement, or spread beyond the capsule.
Treatment
In localized BIA-ALCL, the cornerstone of treatment is surgical removal of the implant and the surrounding capsule, a procedure often known as complete capsulectomy. In early-stage disease, limited to the capsule or periprosthetic fluid, complete surgical removal can be highly effective. This is one of the reasons why early diagnosis is so important.
More advanced cases may require additional treatments, such as chemotherapy, radiation therapy, targeted therapy, or multidisciplinary oncologic management. Treatment decisions depend on the extent of the disease, pathology findings, the patient’s condition, and specialist evaluation. Because BIA-ALCL is rare, its management should ideally involve teams familiar with implant-associated lymphomas, including plastic surgeons, oncologists, hematologists, pathologists, and radiologists.
Should people with breast implants be alarmed?
The risk of BIA-ALCL is considered low, but it is clinically important. The goal is not to create fear, but to promote informed decisions and appropriate surveillance. Many health authorities do not recommend removing breast implants in people without symptoms solely because of fear of BIA-ALCL. However, patients should know the warning signs and discuss their implant type, surgical history, and follow-up plan with their healthcare provider.
This is especially relevant for people with textured implants or implants placed many years ago. Knowing the implant brand, surface type, and date of placement can be useful. If a patient does not know these details, a surgeon or medical record may help clarify them.
Breast Implants, BIA-ALCL, and Other Rare Cancers
BIA-ALCL is the best-known implant-associated cancer, but recent safety communications have also discussed rare reports of other malignancies arising in the capsule around breast implants, including squamous cell carcinoma and other lymphomas. These events appear to be very uncommon, and their risk factors are less understood than those of BIA-ALCL.
This emerging evidence reinforces an important principle: breast implants are medical devices that require long-term awareness and follow-up. They are not considered lifetime devices, and patients may need monitoring or future surgeries for complications unrelated to cancer, such as rupture, capsular contracture, pain, infection, or aesthetic changes.
The most important message is awareness. New swelling, pain, a mass, asymmetry, or persistent changes around a breast implant should not be ignored, especially if they appear years after surgery. Early evaluation can make a major difference.
This article is intended for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment. If you have breast implants and notice swelling, pain, a lump, asymmetry, or any persistent change, consult a qualified healthcare professional.
Main reference:
Bosc R. (2025). Prothèses et cancer : le lymphome anaplasique à grandes cellules [Breast implant and cancer, BIA-ALC]. Annales de chirurgie plastique et esthetique, 70(6), 572–580. https://doi.org/10.1016/j.anplas.2025.05.019
Other references:
Clemens, M. W., Jacobsen, E. D., Horwitz, S. M., Brody, G. S., Deva, A. K., & Kim, B. (2019). 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma. Aesthetic Surgery Journal, 39(Suppl_1), S3–S13. https://pubmed.ncbi.nlm.nih.gov/30715173/
Marra, A., Viale, G., Pileri, S. A., Pravettoni, G., Viale, G., & De Lorenzi, F. (2020). Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. Cancer Treatment Reviews, 84, 101963. https://pubmed.ncbi.nlm.nih.gov/31958739/
